Evidence map›Paper›PMID 37561769›Full record

ArticlePloS one2023

Vector autoregression: Useful in rare diseases?-Predicting organ response patterns in a rare case of secondary AA amyloidosis.

Sandra M Ihne-Schubert, Malte Kircher, Rudolf A Werner, Constantin Lapa, Hermann Einsele, Andreas Geier, Torben Schubert

Open access · goldAbstract readCase Reports
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sandra M Ihne-SchubertInterdisciplinary Amyloidosis Center of Northern Bavaria, University and University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0001-8540-7122
Malte KircherNuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.ORCID 0000-0003-4355-0881
Rudolf A WernerDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Constantin LapaNuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.
Hermann EinseleInterdisciplinary Amyloidosis Center of Northern Bavaria, University and University Hospital Würzburg, Würzburg, Germany.
Andreas GeierInterdisciplinary Amyloidosis Center of Northern Bavaria, University and University Hospital Würzburg, Würzburg, Germany.
Torben SchubertCIRCLE-Centre for Innovation Research, Lund University, Lund, Sweden.
Universitätsklinikum Würzburg · DELund University · SEUniversity of Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStatistical analyses of clinical data are a cornerstone in understanding pathomechanisms of disorders. In rare disorders, cross-sectional datasets of sufficient size are usually not available. Taking AA amyloidosis as an example of a life-threatening rare disorder resulting from of uncontrolled chronic inflammation, we propose techniques from time series analysis to predict organ response to treatment. The advantage of time-series analysis is that it solely relies on temporal variation and therefore allows analyzing organ response to treatment even when the cross-sectional dimension is small.

methodsThe joint temporal interdependence of inflammatory activity and organ response was modelled multivariately using vector autoregression (VAR) based on a unique 4.5 year spanning data set of routine laboratory, imaging data (e.g., 18F-Florbetaben-PET/CT) and functional investigations of a 68-year-old patient with multi-organ involvement of AA amyloidosis due to ongoing inflammatory activity of a malignant paraganglioma in stable disease for >20 years and excellent response to tocilizumab).

resultsVAR analysis showed that alterations in inflammatory activity forecasted alkaline phosphatase (AP). AP levels, but not inflammatory activity at the previous measurement time point predicted proteinuria.

conclusionWe demonstrate the feasibility and value of time series analysis for obtaining clinically reliable information when the rarity of a disease prevents conventional prognostic modelling approaches. We illustrate the comparative utility of blood, functional and imaging markers to monitor the development and regression of AA amyloidosis.

Indexed as

AmyloidosisPositron Emission Tomography Computed TomographyAgedCross-Sectional StudiesHumansRare DiseasesSerum Amyloid A ProteinSerum Amyloid A Protein

Identifiers

PMID37561769
PMCPMC10414553
OpenAlexW4385732615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.